Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer

Kaohsiung Journal of Medical Sciences

Volumn 30, Issue 2, 2014, Pages 82-85

  Zhu, Yi Ping ^a,b   Yao, Xu Dong ^a,b   Zhang, Shi Lin ^a,b   Dai, Bo ^a,b   Zhang, Hai Liang ^a,b   Shen, Yi Jun ^a,b   Zhu, Yao ^a,b   Shi, Guo Hai ^a,b   Lin, Guo Wen ^a,b   Ye, Ding Wei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Castration resistant prostate cancer; Chemotherapy; Etoposide; Oral

Indexed keywords

ANTIANDROGEN; ETOPOSIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANTIANDROGEN THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; TREATMENT DURATION; VERY ELDERLY;

CASTRATION-RESISTANT PROSTATE CANCER; CHEMOTHERAPY; ETOPOSIDE; ORAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROSTATIC NEOPLASMS;

EID: 84892827554     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.kjms.2013.07.004     Document Type: Article

References (12)

1. X. Huang, C.H. Chau, and W.D. Figg Sr. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures J Hematol Oncol 2 2012 35
2. G.W. Lin, D.W. Ye, X.D. Yao, S.L. Zhang, B. Dai, and H.L. Zhang et al. Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer Chin Med J 28 2012 520 523
3. V. Serretta, V. Altieri, G. Morgia, A. Siragusa, G. De Grande, and M. Napoli et al. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital Urol Int 83 2009 452 457
4. G. Spitaleri, D.V. Matei, G. Curigliano, S. Detti, F. Verweij, and S. Zambito et al. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer Ann Oncol 20 2009 498 502
5. A. Berruti, E. Fara, M. Tucci, R. Tarabuzzi, A. Mosca, and C. Terrone et al. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up Urol Oncol 23 2005 1 7 (Pubitemid 40692259)
6. H.G. Munshi, K.J. Pienta, and D.C. Smith Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide Cancer 1 2001 2175 2180 (Pubitemid 32476383)
7. K. Fujikawa-Yamamoto, T. Ota, M. Miyagoshi, and H. Yamagishi Effects of etoposide on the proliferation of hexaploid H1 (ES) cells Hum Cell 25 2012 45 50
8. M.L. Slevin, P.I. Clark, S.P. Joel, S. Malik, R.J. Osborne, and W.M. Gregory et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer J Clin Oncol 7 1989 1333 1340 (Pubitemid 19220137)
9. M.H. Hussain, K.J. Pienta, B.G. Redman, G.D. Cummings, and L.E. Flaherty Oral etoposide in the treatment of hormone-refractory prostate cancer Cancer 1 1994 100 103 (Pubitemid 24187617)
10. P. Yuan, B.H. Xu, J.Y. Wang, F. Ma, Y. Fan, and Q. Li et al. Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy Chin Med J 125 2012 775 779
11. E.J. Small, and S. Srinivas The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer Cancer 15 1995 1428 1434
12. W.K. Kelly, H.I. Scher, M. Mazumbar, V. Vlamis, M. Schwartz, and S.D. Fossa Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607 615 (Pubitemid 23105667)